UK Biotechnology group Vernalis said on Wednesday it will cut over half its workforce to preserve cash and its chief executive Simon Sturge will step down, following last year's rejection of its key Frova MM (menstrual migraine) drug in the United States.
Vernalis said it will reduce headcount from 210 to about 90, although it would retain a research and development workforce.
No comments:
Post a Comment